ArticleCureus2026
Cabergoline-Resistant Recurrent Macroprolactinoma During Pregnancy: A Case Report and Review of the Literature.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a rare case of cabergoline-resistant recurrent macroprolactinoma during pregnancy. A 34-year-old woman, 17 weeks pregnant, presented with a four-week history of headache and a one-day history of visual disturbance. The medical history was significant for a macroprolactinoma with pituitary apoplexy, which was treated with an emergent pituitary resection approximately two years and four months before this presentation. At that time, postoperative prolactin levels improved but remained elevated despite gradually escalating cabergoline doses up to 6 mg per week. Our patient met the established criteria for cabergoline resistance, with persistently elevated prolactin levels despite high-dose cabergoline therapy. She was dealing with resistant hyperprolactinemia, causing infertility. The patient decided to conceive, and pre-pregnancy counseling was done by reproductive endocrinology, maternal-fetal medicine, and a genetic counselor. Before conception, magnetic resonance imaging (MRI) of the pituitary showed postoperative changes from transsphenoidal hypophysectomy and expanded partial sella, with no clear tumor, and the prolactin level was 228 ng/mL (non-pregnant normal reference range: 3-30 ng/mL). She had in vitro fertilization done, and cabergoline was discontinued on confirmation of pregnancy. On presentation, MRI of the pituitary revealed a recurrent pituitary macroadenoma (29 × 29 × 27 mm). She developed symptomatic tumor recurrence within three months of stopping cabergoline, and her prolactin level was 1,669.8 ng/mL (normal reference range in pregnancy: 10-209 ng/mL). She was treated with steroids, and cabergoline was restarted. However, the tumor continued to grow, causing symptoms necessitating repeat urgent pituitary resection in the second trimester of pregnancy. She remained on cabergoline through the rest of her pregnancy and delivered a healthy male neonate via cesarean section, done for breech presentation at 39 weeks. The postpartum, fetal, and neonatal stages were all uneventful. This case highlights the complexities of managing dopamine agonist-resistant macroprolactinomas during pregnancy and underscores the importance of individualized, multidisciplinary decision-making to optimize maternal and fetal outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.